ArticleFrontiers in oncology2025
Evaluating the impact of immune checkpoint inhibitors on liver steatosis and function: a retrospective cohort analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) are an essential class of immunotherapy drugs for cancer, but their impact on chronic inflammatory conditions remains unclear. Liver attenuation, a non-invasive measure of liver steatosis on CT, offers a way to assess liver inflammation. This study evaluates the impact of ICI therapy on liver attenuation and liver enzyme levels in cancer patients, building on prior research with a larger cohort. Methods: We conducted a retrospective cohort study of 164 cancer patients treated with ICIs at Vanderbilt University Medical Center between 2017 and 2022. Liver attenuation and enzyme levels (total bilirubin, AST, ALT, and alkaline phosphatase) were analyzed before and after ≥1 year of ICI therapy. Clinical factors such as weight change, liver metastasis, and steroid use were also assessed. Hepatic adverse events were characterized using CTCAE v5.0 criteria. Results: No significant changes in liver attenuation were observed from baseline to post-treatment (59.86 ± 8.07 HU vs 59.38 ± 8.36 HU, p = 0.42). Liver enzyme levels also remained stable. Post-treatment liver abnormalities occurred in 23 patients (14.0%), with most being Grade 1 elevations (11.0%). Increased body weight was significantly associated with lower liver attenuation (p < 0.0001), and liver metastasis correlated with higher total bilirubin (p < 0.001) and AST levels (p < 0.01). Conclusion: ICIs did not significantly change liver attenuation or enzyme levels, suggesting they may not exacerbate liver fat deposition or subclinical injury. Further research with additional imaging modalities is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.